ERBB2 and breast cancer: The introduction into clinical practice of RNA-based assays that subtype BC by intrinsic biology and prognosis is well established for clinical decision-making in early ER+BC, and recent studies suggest potential value in metastatic, and in clinically HER2-positive disease15–19.